comparemela.com

Stina Singel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2.

United statesChicago mayStina singelMelinda bakerAscendis pharmaTim leeHead of clinical developmentExchange commissionPatti bankAmerican society of clinical oncologyBelieve trialAmerican societyClinical oncologyExecutive vice presidentClinical developmentAscendi annual report

Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript

Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.

United kingdomGavin clark gartnerJessica fyeStina singelTim leeJoseph schwartzDavid lebowitzLi watsekAscendis pharmaJan mikkelsenRosemary liJoe kellyScott smithRegulatory agencyClinical developmentInternational market

Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.

United statesJessica fyeJoseph schwartzTim leeDavid lebowitzAscendis pharmaLi watsekStina singelJan mikkelsenJoe kellyScott smithTazeen ahmadTimothy leeHead of clinical developmentEuropean commissionCall transcript february

Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript

Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.

United kingdomTim leeJessica fyeScott smithTranscon ptasJan mikkelsenStina singelAscendis pharmaPaul choiTimothy leeEuropean commissionEuropean unionGoldman sachsHead of clinical development oncologyOsaka universityCall transcript november

Ascendis Presents Updated and New TransCon IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

26.10.2023 - Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy TransCon IL-2 β⁄γ administered every . Seite 1

Stina singelAscendis pharmaHead of clinical developmentEuropean society of medical oncologyBelieve trialEuropean societyMedical oncologyExecutive vice presidentClinical developmentAscendis pharma chartScendis pharma kursScendis pharma aktie

vimarsana © 2020. All Rights Reserved.